Insurance That Covers Mounjaro: The UK Reality

The biggest misconception: insurance 'covers' Mounjaro the way it might cover surgery

A question our prescribers hear most weeks is some version of: "Can I claim Mounjaro on my Bupa/AXA/Vitality policy?" The expectation, understandably, is that private health cover should work like it does for a consultation or a procedure. For Mounjaro, it almost never does.

UK private medical insurance policies draw a firm line between acute treatment and what they classify as chronic lifestyle conditions. Weight management medicines, including Mounjaro, typically fall on the wrong side of that line. Most major UK insurers either exclude weight-loss medicines categorically or list obesity treatment as a standard exclusion. Some policies will fund the initial specialist consultation that results in a prescription, but stop short of covering the medicine itself. If you hold a policy, it is worth reading the exclusions section carefully or calling your insurer directly, but do not assume coverage exists before you do.

There is no regulatory requirement for UK insurers to cover prescription weight-management medicines, and no government scheme changes that for private policyholders. The NHS is the public route; insurance is a separate private arrangement entirely. These are genuinely different systems, and it matters to understand which one applies to your situation before making plans.

NHS access: clinical criteria, not your insurance status, decide eligibility

On the NHS, Mounjaro is recommended by NICE under technology appraisal TA1026 for adults with a BMI of 35 or above plus at least one qualifying weight-related condition. The five qualifying conditions listed are high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Whether or not you hold private insurance has no bearing whatsoever on NHS eligibility.

The rollout is phased. From June 2025, people with a BMI of 40 or above and four or more qualifying conditions became eligible. A second cohort, covering BMI 35 to 39.9 with four or more conditions, opened from June 2026. Further cohorts are planned through 2027. GP practices can prescribe under the 2026 QOF contract, though participation varies by practice and area, so waiting times differ significantly across the country. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

If you are curious whether the NHS route fits your profile, the Mounjaro overview page on this site explains the criteria in more detail, and NHS England's guidance on weight-management injections sets out what to expect from your GP.

What private treatment actually costs, and what insurance won't change

Since Eli Lilly's UK list-price increase in September 2025, private Mounjaro costs have risen noticeably. Reported prices across providers now range roughly £149 to £375 per month depending on dose, the higher doses carry the higher prices. You can read more about that in the detail on the Eli Lilly UK price change. What those figures don't always reflect is everything a legitimate private service should include: clinical assessment, prescription, aftercare support and tracked delivery.

Because insurance won't bridge that gap for most people, the practical question becomes whether private treatment through a regulated pharmacy is the right route. That depends on your clinical suitability, which a prescriber decides after reviewing your health history, current medicines and weight. Mounjaro works as a dual GIP and GLP-1 receptor agonist (the only medicine of its kind licensed for weight management in the UK) and the trial results, including around 20–21% average body-weight reduction at the highest dose in SURMOUNT-1, make it a treatment worth discussing seriously with a clinician.

The typical weight-loss results page covers the clinical evidence in depth if you want the numbers before booking anything.

Mounjaro as a prescribed medicine: what the clinical assessment covers

Because Mounjaro is a prescription-only medicine, no legitimate UK pharmacy (online or otherwise) can supply it without a prescriber first reviewing your case. That assessment is not a formality. It looks at your BMI, any conditions that affect suitability, your current medicines (some interactions matter, particularly for contraception, women on the pill should discuss adding a non-oral method for the first four weeks of treatment and after each dose increase, because absorption may be affected), and whether you have any history of conditions such as pancreatitis or medullary thyroid carcinoma that would make tirzepatide, the active ingredient in Mounjaro, unsuitable.

Pregnancy, breastfeeding and trying to conceive are all situations where Mounjaro is not recommended. Under-18s are not a licensed group. If you have questions about Mounjaro and insulin resistance or how it interacts with existing conditions, those are exactly the kinds of things a prescriber should talk through with you.

If you are not sure where to start, the frequently asked questions cover many of the common concerns, and our clinical team reviews every consultation personally. At the end of that process, if Mounjaro is clinically appropriate, treatment can be dispatched the same working day from our GPhC-registered pharmacy (registration number 9012878, verifiable on the GPhC register). That won't appear on an insurance policy. But it is a clear, legal and clinically supervised route for people who are suitable and don't want to wait.

If private treatment sounds like the right next step, you can speak to our prescribers through a free consultation, no commitment, no charge, and a real clinician reviews your answers the same day.